This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
R&D and Business Briefing in NYC on 21 May
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Deutsche Bank 39
th Annual Health Care Conference to be held at the InterContinental Boston Hotel in Boston, MA.
Flemming Pedersen, CFO and EVP, presents the Company and provides an overview of the Company and its key programmes on 8 May 2014 at 10:00 AM EDT.
On 21 May 2014, ALK will be hosting an R&D and business briefing for institutional investors, equity research analysts and media in New York City. Further details will be available closer to the date. Any questions regarding this event can be directed to Janet Dally at
firstname.lastname@example.org (+1 609-466-0466). Please use this link to register online:
https://www.regonline.com/AlkbusinessbriefingALK-Abello A/SFor further information please contact:Investor Relations:Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525Janet Dally, tel. +1 609 466 0466, mobile +1 732 319 2833, e-mail:
email@example.comPress:Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143
About ALKALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy - a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck and Torii to commercialise sublingual allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hoersholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.